Over the past 30 years, extensive research has explored the use of nutritional supplements for prevention of cancer. Despite what appears to be strong observational evidence, randomized clinical trials of beta carotene, ascorbic acid, alpha tocopherol, selenium, and folic acid all failed to show evidence of efficacy for cancer chemoprevention. 1,2 The colorectum has been particularly well studied: trials of these interventions examining adenoma recurrence have been uniformly negative as well. 3,4 The latest supplement of interest is vitamin D. Observational studies have consistently found that high vitamin D status, as measured by circulating 25-hydroxyvitamin D (25[OH]D) is inversely related to the risk of colorectal cancer. 5 However, high 25(OH)D levels may be a marker of "good health," a trait that observational studies may not be able to fully control for in analysis. Two recent clinical trials failed to find a chemopreventive benefit of vitamin D 3 supplementation. In the VITAL trial, 2000 IU/d for a median of 5.3 years did not reduce risk of all cancer or colorectal cancer. 6 This may have been due to the short follow-up in the context of the long latent period for carcinogenesis. In another trial reported in 2015, 1000 IU/d of vitamin D 3 for 3 to 5 years did not reduce adenoma recurrence, and although the follow-up period was sufficient to assess this risk, the dosage of vitamin D in that trial may have been too low. 7 A separate but related issue is whether vitamin D supplementation could be used to improve outcomes in patients with cancer. In this issue of JAMA, the first clinical trials of vitamin D 3 supplementation in patients with advanced or metastatic colorectal cancer (the SUNSHINE trial) 8 or luminal gastrointestinal cancer (the AMATERASU trial) 9 are reported. There are data motivating these trials. A meta-analysis reported a statistically significant association between higher 25(OH)D concentrations measured at or near the time of cancer diagnosis and reduced overall and cancer-specific mortality, including colorectal cancer. 10 However, there are few data suggesting similar associations for cancers of the stomach and esophagus.The SUNSHINE phase 2 trial conducted in North America investigated oral supplementation with vitamin D 3 added to standard chemotherapy in 139 patients with unresectable advanced or metastatic colorectal cancer, and compared highdose vitamin D 3 (8000 IU/d for 2 weeks and 4000 IU/d thereafter) with standard-dose vitamin D 3 (400 IU/d). 8 Participants randomized to receive high-dose vitamin D 3 experienced